Ep. 156 - JPM Highlights & Alzheimer's Takeaways - BioCentury This Week

Om avsnittet

A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.

Reach us by sending a text

Ep. 156 - JPM Highlights & Alzheimer's Takeaways

Om avsnittet

Fler avsnitt

Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Ep. 384 - Back to School Special: The global FIH trials race

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA